BASKING RIDGE, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- All customers with telephone numbers with the 347/718/917/929 area codes should be aware of the introduction of the new 465 area code. Beginning June 18, 2026, customers ordering new telephone lines or services in the boroughs of the Bronx, Brooklyn, Queens, Staten Island as well as the Marble Hill section of Manhattan may be assigned numbers using the new 465 area code.
Company unveils evolved brand reflecting expanded capabilities in AI, cybersecurity, strategic services, and innovation.DENVER, June 8, 2026 /PRNewswire/ -- New Charter Technologies, an IT...
Company appoints COO and new executive team, opens Texas office, expands into UKI, and earns top national reseller rankings. Recognized with three Global InfoSec Awards.NEW...
New Facility, Open July 1st, Supports Continued Growth and Reflects Market Shift Toward Centralized Execution, and Lifecycle-Driven Service Supply chainsPARSIPPANY, N.J., June 8, 2026...
HONG KONG, June 8, 2026 /PRNewswire/ -- The Fourth "Victoria Harbour Night Talk" concluded successfully on June 5 at Cloud 39, The Henderson, Central,...
Basel, June 8th, 2026 – Novartis will present data from 10 abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026, spanning Rhapsido® (remibrutinib) clinical trial results and real-world evidence on patient burden and treatment experience. Highlights include two late-breaking oral presentations; the Phase III RemIND trial for Rhapsido in chronic inducible urticaria (CIndU) and extension data from the Phase IIIb REMIXED trial in chronic spontaneous urticaria (CSU).
“The Rhapsido presentations at EAACI 2026 expand our understanding of BTK inhibition across multiple immune-mediated diseases and provide evidence of its potential to make a meaningful impact for patients who continue to face significant burden and limited treatment options,” said Angelika Jahreis, Global Head, Immunology Development, Novartis. “Novartis will present Rhapsido data from a long-term extension trial in chronic spontaneous urticaria, Phase III data in three types of chronic inducible urticaria, and early Phase II dose-response analysis for food allergy – together providing scientific evidence for its impact across numerous diseases.”
THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, ITALY, DENMARK, JAPAN, THE UNITED STATES, OR TO ANY NATIONAL OF SUCH JURISDICTIONS
Increased AI deployment results in an aggregated net hiring effect of +27% expected in 2026, while upskilling internal talent emerges as the primary strategy...
Most surveyed technology leaders are accountable for systems they don't fully controlOnly 11% of respondents say they're completely prepared for the scale of AI...
HOOFDDORP, Netherlands, June 8, 2026 /PRNewswire/ -- EZVIZ, a world-leading smart home brand, announced to enter a new chapter of its EZVIZ Green Initiative by expanding...